siRNA, drug and application thereof for inhibiting CIDEB gene expression
By optimizing the siRNA sequence and Galnac delivery vector, the expression of the CIDEB gene was specifically inhibited, solving the problem of inhibiting CIDEB expression in existing technologies and achieving effective treatment for metabolic diseases such as fatty liver disease.
Patent Information
- Application Number
- CN202380012566.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-11-21
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2043-11-21
AI Technical Summary
Existing technologies are unable to effectively inhibit CIDEB gene expression, leading to the occurrence and development of metabolic diseases such as fatty liver disease. Furthermore, existing siRNA drugs have the problem of strong non-target activity.
A series of siRNA sequences, including BBD-4101 and BBD-4102, were designed and optimized. Through base optimization and modification, combined with Galnac derivative delivery vectors, they specifically inhibited CIDEB gene expression and reduced non-target activity.
It showed significant CIDEB expression inhibition in in vitro and in vivo experiments, improved liver fibrosis levels, and had broad protective effects, making it suitable for the treatment of various CIDEB-related diseases.
Smart Images

Figure QLYQS_1 
Figure QLYQS_2 
Figure QLYQS_3
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomedicine, and specifically relates to siRNA, medicine and application thereof for inhibiting CIDEB gene expression. Background Art
[0002] A considerable part of the current global health problems comes from diseases caused by fatty liver, such as cirrhosis. Disturbance of lipid homeostasis is an important factor in the occurrence and development of cirrhosis and metabolic syndrome (including obesity, diabetes, cardiovascular disease and cancer). Hepatic lipid balance, including lipid storage and assembly and secretion of very low-density lipoprotein. Free fatty acids are remodeled and esterified into neutral lipids through lipogenesis and stored in lipid droplets. The lipid storage capacity of lipid droplets is controlled by their growth, which can be controlled by local lipid synthesis or lipid droplet fusion. Lipid droplets are dynamic subcellular organelles composed of a phospholipid monolayer envelope, a neutral lipid core and a series of specific lipid droplet-associated proteins, which maintain the dynamic balance of lipids by coordinating lipid synthesis, lipid storage, lipid secretion and lipolysis. Cellular uptake of fats, cholesterol and ceramides are remodeled and esterified into neutral lipids through the lipogenesis pathway on the endoplasmic reticulum and sequestered into the lipid droplet core. These neutral lipids include triglycerides, sterol esters and acylated ceramides as well as other esterified lipids. Studies have shown that dysfunctional or excessive storage of neutral lipids in cells is closely related to the development of metabolic diseases such as obesity, type 2 diabetes, non-alcoholic fatty liver disease, and atherosclerosis.
[0003] So far, several proteins associated with lipid droplets have been reported. Among them, the CIDEB gene is the most highly expressed in human liver. It is a liver-specific protein that is localized in the endoplasmic reticulum and lipid droplets and is an important regulator of lipid storage and lipid metabolism in adipocytes. CIDEB is enriched at lipid droplet-lipid droplet contact sites, mediates directional lipid transfer from small to large lipid droplets, and controls the fusion and growth of atypical lipid droplets. The growth of LDs enhances fat storage capacity and intracellular fat accumulation. However, uncontrolled lipid droplet growth (hypertrophy) in adipose tissue or liver due to excessive fat intake may lead to the development of metabolic diseases such as obesity and fatty liver disease. Exome sequencing in hundreds of thousands of people showed that the burden of rare predicted loss-of-function variants and missense variants in CIDEB (combined carrier frequency, 0.7%) was significantly associated with reduced alanine aminotransferase levels (1.24 U / L lower per allele beta) and a 33% lower risk of all-cause liver disease (hazard ratio of 0.67 per allele).
[0004] Studies have shown that mutations in CIDEB can prevent fat from accumulating in liver cells and produce smaller lipid droplets, which is associated with a 33% decrease in the risk of liver disease. Developing drugs targeting protective genetic variants is a common idea. Previously, the siRNA drug inclisiran targeting PCSK9 has been approved by the FDA for marketing. As a long-acting lipid-lowering drug, inclisiran only needs to be injected subcutaneously twice a year to effectively reduce the level of low-density lipoprotein in the blood circulation and achieve the effect of lowering blood lipids. The advantage of developing siRNA drugs targeting CIDEB is the breadth of its protective effect, which is not limited to a certain type of liver disease. Summary of the invention
[0005] Based on this, the purpose of the present invention is to provide a siRNA for inhibiting CIDEB expression and its application, which has the advantages of good in vitro and in vivo test effects and weak non-target activity.
[0006] The first aspect of the present invention provides an siRNA for reducing the expression of DFFA-like effector B (Cell death-inducing DFFA-like effector b, CIDEB) in human cells, which comprises a sense chain and an antisense chain, wherein the sense chain and the antisense chain are complementary, and the sequence thereof is selected from any group of duplexes shown in Table 1 or at least 15 consecutive nucleotide sequences whose composition differs by no more than 3 nucleotides, including the sequences shown in BBD-4102, BBD-4101 and BBD-4005, wherein the sequences shown in BBD-4102 and BBD-4101 are obtained by base optimization of BBD-4005.
[0007] In some embodiments, the siRNA for inhibiting CIDEB expression comprises a sense strand and an antisense strand, and the sequence thereof is selected from at least one pair of the following sequences or a modified sequence thereof:
[0008] a) BBD-4101, the sense strand of which is shown in SEQ ID NO.201, and the antisense strand of which is shown in SEQ ID NO.202;
[0009] b) BBD-4102, the sense strand of which is shown in SEQ ID NO.203, and the antisense strand of which is shown in SEQ ID NO.204;
[0010] c) BBD-4005, the sense strand of which is shown in SEQ ID NO.9, and the antisense strand of which is shown in SEQ ID NO.10;
[0011] d) BBD-4012, the sense strand of which is shown in SEQ ID NO.23, and the antisense strand of which is shown in SEQ ID NO.24;
[0012] e) BBD-4013, the sense strand of which is shown in SEQ ID NO.25, and the antisense strand of which is shown in SEQ ID NO.26;
[0013] f) BBD-4015, the sense strand of which is shown in SEQ ID NO.29, and the antisense strand of which is shown in SEQ ID NO.30;
[0014] g) BBD-4016, the sense strand of which is shown in SEQ ID NO.31, and the antisense strand of which is shown in SEQ ID NO.32;
[0015] h) BBD-4018, the sense strand of which is shown in SEQ ID NO.35, and the antisense strand of which is shown in SEQ ID NO.36;
[0016] i) BBD-4020, the sense strand of which is shown in SEQ ID NO.39, and the antisense strand of which is shown in SEQ ID NO.40;
[0017] j) BBD-4021, the sense strand of which is shown in SEQ ID NO.41, and the antisense strand of which is shown in SEQ ID NO.42;
[0018] k) BBD-4022, the sense strand of which is shown in SEQ ID NO.43, and the antisense strand of which is shown in SEQ ID NO.44;
[0019] l) BBD-4023, the sense strand of which is shown in SEQ ID NO.45, and the antisense strand of which is shown in SEQ ID NO.46;
[0020] m) BBD-4026, the sense strand of which is shown in SEQ ID NO.51, and the antisense strand of which is shown in SEQ ID NO.52;
[0021] n) BBD-4027, the sense strand of which is shown in SEQ ID NO.53, and the antisense strand of which is shown in SEQ ID NO.54;
[0022] o) BBD-4039, the sense strand of which is shown in SEQ ID NO.77, and the antisense strand of which is shown in SEQ ID NO.78;
[0023] p) BBD-4040, the sense strand of which is shown in SEQ ID NO.79, and the antisense strand of which is shown in SEQ ID NO.80;
[0024] q) BBD-4045, the sense strand of which is shown in SEQ ID NO.89, and the antisense strand of which is shown in SEQ ID NO.90;
[0025] r) BBD-4052, the sense strand of which is shown in SEQ ID NO.103, and the antisense strand of which is shown in SEQ ID NO.104;
[0026] s) BBD-4057, the sense strand of which is shown in SEQ ID NO.113, and the antisense strand of which is shown in SEQ ID NO.114;
[0027] t) BBD-4061, the sense strand of which is shown in SEQ ID NO.121, and the antisense strand of which is shown in SEQ ID NO.122;
[0028] u) BBD-4064, the sense strand of which is shown in SEQ ID NO.127, and the antisense strand of which is shown in SEQ ID NO.128;
[0029] v) BBD-4066, the sense strand of which is shown in SEQ ID NO.131, and the antisense strand of which is shown in SEQ ID NO.132;
[0030] w) BBD-4074, the sense strand of which is shown in SEQ ID NO.147, and the antisense strand of which is shown in SEQ ID NO.148;
[0031] x) BBD-4078, the sense strand of which is shown in SEQ ID NO.155, and the antisense strand of which is shown in SEQ ID NO.156;
[0032] y) BBD-4097, the sense strand of which is shown in SEQ ID NO.193, and the antisense strand of which is shown in SEQ ID NO.194;
[0033] z) BBD-4100, the sense strand of which is shown in SEQ ID NO.199, and the antisense strand of which is shown in SEQ ID NO.200.
[0034] In some embodiments, the siRNA is selected from the sequences shown in BBD-4101, BBD-4102, BBD-4005 and BBD-4012 or modified sequences thereof.
[0035] In some of the embodiments, the sense strand comprises no more than 3, 2, 1 or 0 unmodified nucleotides, the modified nucleotides in the sense strand comprise 2'-O-methyl modified nucleotides, 2'-deoxy nucleotides, 2'-fluorine modified nucleotides, terminal inverted abasic residues, locked nucleic acids (LNA), and the sense strand contains 1, or 2, or 3 phosphorothioate bonds at the 5'-end; and the antisense strand comprises no more than 3, 2, 1 or 0 unmodified nucleotides, the modified nucleotides in the antisense strand comprise 2'-O-methyl modified nucleotides, 2'-deoxy nucleotides, 2'-fluorine modified nucleotides, terminal 5'-(E)-vinylphosphonate nucleotides and analogs thereof, open ring nucleic acid nucleotides (UNA) or isoglycerol nucleotides (isoGNA), and the antisense strand contains 1-3 phosphorothioate bonds at the 5'-end and 3'-end respectively.
[0036] Wherein, the uridine-5'-end-(E)-vinylphosphonic acid group and its analogs are selected from one of the following structures:
[0037]
[0038] Where: R is XG,
[0039] X is selected from: -C(R 8 )(R 9 )-, -S-;
[0040] R 8 and R 9 are independently selected from: H, C1-C6 alkyl, halogen; G is selected from: H, halogen, cyano, C1-C 10 Alkyl, C2-C 10 Alkenyl, C2-C 10 Alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkylmethyl, C1-C 10 Alkoxy, halogen-substituted C1-C 10 Alkyl, hydroxy substituted C1-C 10 Alkyl, C1-C6 alkoxy substituted C1-C 10 Alkyl, amino substituted C1-C 10 Alkyl, C1-C6 alkylamino substituted C1-C 10 Alkyl, cyano substituted C1-C 10 alkyl.
[0041] Preferably, R is selected from the group consisting of methylthio, ethylthio, ethyl, propyl, allyl, methoxymethyl, methoxyethyl, cyanomethyl, and fluoromethyl.
[0042] 5'(E)-vinylphosphonate, abbreviated as vp-, the terminal 5'(E)-vinylphosphonate nucleotide is an RNA nucleotide, especially VP-U. More preferably, the uridine-5'-terminal-(E)-vinylphosphonate group is in the analogue 2'-S-methyluridine-5'-
[0043] (E)-vinyl phosphate-3'-phosphate, or 2'-O-methyluridine-5'-(E)-vinyl phosphate-3'-phosphate.
[0044] Wherein, the isoglycerol nucleotide modification is as shown in formula (I):
[0045]
[0046] Wherein, M is O or S;
[0047] Base is selected from any one of purine, adenine, guanine, isoguanine, hypoxanthine, xanthine, C2 modified purine, N8 modified purine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, N6-alkyladenine, O6-alkylguanine, 7-deazapurine, cytosine, 5-methylcytosine, isocytosine, pseudocytosine, uracil, pseudouracil, 2-thiouridine, 4-thiouridine, C5 modified pyrimidine, thymine, indole, 5-nitroindole and 3-nitropyrrole. Preferably, wherein the modified nucleotide of formula (I) is at least one of the following:
[0048]
[0049] Any of the siRNAs, wherein the siRNA sense strand is 21 base-containing nucleotides and the antisense strand is 23 base-containing nucleotides,
[0050] The 3' to 5' modification of the sense strand is as follows:
[0051] u mA mmmmmmmymdvfmymmmmmmu, the 5'-3' base modification of the antisense strand is as follows:
[0052] vpU fmmmmxymmmdmfmfmymmmm m;
[0053] Or when the sense strand of siRNA is 21 base-containing nucleotides and the antisense strand is 21 base-containing nucleotides,
[0054] The 3' to 5' modification of the sense strand is as follows:
[0055] u mA mmmmmmmymdvfmymmmmmmu,
[0056] The 5'-3' modification of the antisense strand is as follows:
[0057] vpU fmmmmxymmmdmfmfmymmm;
[0058] Or when the sense strand of siRNA is 19 base-containing nucleotides and the antisense strand is 21 base-containing nucleotides,
[0059] The 3' to 5' modification of the sense strand is as follows:
[0060] u mA mmmmmmmymdvfmymmmmu,
[0061] The 5'-3' modification of the antisense strand is as follows:
[0062] vpU fmmmmxymmmdmfmfmymmm;
[0063] wherein vpU is uridine-5'-terminal-(E)-vinylphosphonate and its analogs, mA is 2'-O-methyladenosine-3'-phosphate, m is any 2'-O-methyl modified nucleotide, f is any 2'-fluorine modified nucleotide, x is any 2'-O-methyl modified nucleotide or open nucleic acid nucleotide (UNA) or isoglycerol nucleotide (isoGNA), y is any 2'-O-methyl modified nucleotide or any 2'-fluorine modified nucleotide, d is any 2'-deoxy nucleotide or 2'-fluorine modified nucleotide, v is any 2'-fluorine modified nucleotide or any 2'-O-methyl modified nucleotide or any 2'-deoxy nucleotide, and u is 0-1 inverted abasic residue.
[0064] In some preferred embodiments, the siRNA is composed of BBD-4101, BBD-4102, BBD-4005 and
[0065] BBD-4012 was obtained by modification in the above manner.
[0066] In some preferred embodiments, the siRNA is a modified duplex in Table 12,
[0067] Further preferably, the siRNA is a modified duplex whose naked sequence is BBD-4101 or BBD-4102 in Table 12.
[0068] More preferably, the siRNA is BBD-4101.11, BBD-4102.11, BBD-4101.21, BBD-4101.24, BBD-4101.31, BBD-4101.41, BBD-4101.33, BBD-4101.43, BBD-4101.34, BBD-4101.44, BBD-4101.45, BBD-4101.46, BBD- 4101.48, BBD-4101.49, BBD-4101.410, BBD-4102.21, BBD-4102.24, BBD-4102.25, BBD-4102.26, B BD-4102.41, BBD-4102.43, BBD-4102.44, BBD-4102.45, BBD-4102.46, BBD-4102.47, BBD-4102.48. More preferred are BBD-4102.41, BBD-4102.44, BBD-4102.42, BBD-4102.47, BBD-4102.43, BBD-4102.48, BBD-4101.41, BBD-4101.48, BBD-4101.45, BBD-4101.49, BBD-4101.46, and BBD-4101.410.
[0069] The second aspect of the present invention provides a pharmaceutical preparation for inhibiting the expression of CIDEB, comprising any of the above-mentioned siRNAs, and a targeted delivery ligand or delivery vector connected to or encapsulated with the siRNA.
[0070] In some embodiments, the ligand is a derivative of N-acetylgalactosamine (Galnac).
[0071] In some embodiments, the structure of the ligand is as follows:
[0072]
[0073]
[0074] In some embodiments, the N-acetylgalactosamine derivative is linked to the 3' end of the sense strand of the siRNA, and the structure is as follows:
[0075]
[0076]
[0077] Above A double-stranded RNA, such as the siRNA of the present invention.
[0078] The third aspect of the present invention provides the use of the above siRNA in the preparation of a biological preparation or a pharmaceutical preparation for inhibiting the expression of CIDEB.
[0079] The fourth aspect of the present invention is to provide the use of the biological preparation or pharmaceutical preparation in the preparation of a method for preventing and treating diseases associated with CIDEB.
[0080] In some embodiments, the disease associated with CIDEB expression is hepatitis, liver fibrosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), cirrhosis, alcoholic steatohepatitis (ASH), alcoholic fatty liver disease (ALD), HCV-related cirrhosis, drug-induced liver injury and hepatocellular necrosis.
[0081] In some embodiments, the diseases associated with CIDEB expression are obesity, diabetes, insulin resistance, hyperglycemia, and various infections caused by diabetes, obesity, metabolic syndrome, and dyslipidemia.
[0082] The fifth aspect of the present invention is to provide a method for inhibiting the expression of CIDEB, comprising administering an effective dose of the above-mentioned siRNA or the above-mentioned biological preparation or pharmaceutical preparation for inhibiting the expression of CIDEB.
[0083] The present invention has studied siRNA sequences and screened multiple siRNA sequences that can be used to inhibit CIDEB expression through a large number of experiments. Based on the previous research on BBD-4005, improvements have been made in terms of sequence base optimization, multiple modification optimization of the sense chain and antisense chain, etc., to better improve the silencing ability of the target and reduce non-target activity. Among them, through a series of in vitro and in vivo experiments, siRNA sequences with better biological activity of inhibiting CIDEB expression were obtained, which are expected to be used in the clinical treatment of diseases related to CIDEB. In particular, it was found that BBD-4101.41 and BBD-4102.41 in these optimized siRNA sequences with good biological activity restored the expression of fibrosis marker genes in the NASH model of mice induced by a high-fat diet, and significantly improved the level of liver fibrosis, which is expected to be used in clinical treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0084] Figure 1 Schematic diagram of the expression results of CIDEB gene and inflammatory fibrosis genes of BBD-4101 and BBD-4102 in the high-fat diet-induced mouse NASH model.
[0085] Figure 2 Schematic diagram of liver HE staining results of BBD-4101 and BBD-4102 in the high-fat diet-induced NASH model in mice. DETAILED DESCRIPTION
[0086] In order to facilitate the understanding of the present invention, the present invention will be described more fully below. The present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive.
[0087] The experimental methods in the following examples without specifying specific conditions are usually carried out according to conventional conditions, such as the fourth edition of Molecular Cloning: A Laboratory Manual edited by Green and Sambrook, published in 2013, or according to the conditions recommended by the manufacturer. The various commonly used chemical reagents used in the examples are all commercially available products.
[0088] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those commonly understood by those skilled in the art to which the present invention belongs. The terms used in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used in the present invention includes any and all combinations of one or more of the related listed items.
[0089] The targeted delivery ligand or other types of delivery carriers of the present invention, wherein the ligand is preferably an N-acetylgalactosamine derivative (Galnac carrier), other types of delivery carriers such as liposomes that are specifically delivered to liver cells can be used in the present invention as long as they can achieve the delivery of siRNA.
[0090] In recent years, GalNAc carriers have been studied in depth. GalNAc-nucleic acid is a monoconjugate formed by a carbohydrate compound and a nucleic acid. N-acetylated galactosamine is covalently conjugated to the 3' and / or 5' end of the sense strand of RNA of different sequences in a trivalent state to form GalNAc-siRNA drugs, thereby achieving specific delivery to hepatocytes, and allowing the drug to enter the cell and function through cellular endocytosis. All known GalNAc carriers are suitable for the siRNA described in the present invention.
[0091] In the following examples, as an example, the structure of the Galnac vector and the siRNA after connection is as follows:
[0092]
[0093] It should be noted that any other GalNAc carrier or liver-targeted liposome with similar effects can be conjugated with the sequence in this document to reduce the expression of CIDBE.
[0094] The abbreviations and structures of nucleotide monomers used in nucleic acid sequence representation are as follows:
[0095] It should be noted that any other GalNAc carrier or liver-targeted liposome with similar effects can be conjugated with the sequence in this document to reduce the expression of CIDBE.
[0096] The abbreviations and structures of nucleotide monomers used in nucleic acid sequence representation are as follows:
[0097] A Adenosine-3'-phosphate T 5'-Methyluridine-3'-phosphate C Cytidine-3'-phosphate G Guanosine-3'-phosphate U Uridine-3'-phosphate dA 2'-deoxyadenosine-3'-phosphate dT 2'-Deoxythymidine-3'-phosphate dC 2'-deoxycytidine-3'-phosphate dG 2'-deoxyguanosine-3'-phosphate Ud 2'-Deoxyuridine-3'-phosphate mA 2'-O-methyladenosine-3'-phosphate mxD 2'-O-methylcytidine-3'-phosphate mxD 2'-O-methylguanosine-3'-phosphate mxD 2'-O-methyluridine-3'-phosphate f 2'-Fluoroadenosine-3'-phosphate f 2'-Fluorocytidine-3'-phosphate f 2'-Fluoroguanosine-3'-phosphate f 2'-Fluorouridine-3'-phosphate VPU 2'-O-methyluridine-5'-(E)-vinylphospho-3'-phosphate VPU-S 2'-S-methyluridine-5'-(E)-vinylphospho-3'-phosphate VPU-8 2'-Methoxymethyl-5'-(E)-vinylphosphonic acid-3'-phosphate VPU-12 2'-S-ethyl-5'-(E)-vinylphosphonic acid-3'-phosphate isoGNA-A Adenosine-isoglycerol nucleotide isoGNA-T Thymidine-isoglycerol nucleotide isoGNA-C Cytidine-isoglycerol nucleotide isoGNA-G Guanosine-isoglycerol nucleotide isoGNA-U Uridine-isoglycerol nucleotide Invab Reverse abasic residue UNA Open-circular nucleic acid nucleotide * Phosphorothioate linkage
[0098]
[0099]
[0100] According to existing techniques, a person skilled in the art can determine that the pharmaceutically acceptable salt of the siRNA may be a sodium salt or a potassium salt. For example, during purification, a sodium salt of the siRNA is produced.
[0101] The present invention is further described in detail below with reference to specific embodiments.
[0102] Example 1 Synthesis of siRNA
[0103] On the 12-channel nucleic acid synthesizer of Beijing Qingke Biotechnology Co., Ltd., 0.2-1 μmol of oligonucleotides were synthesized using a solid-phase oligonucleotide synthesis scheme. The siRNA sequence containing Galnac needs to be synthesized on a CPG pre-filled column coupled with Galnac. Aminolysis reagents were added to the synthesized oligonucleotides and incubated at 45-80°C to separate the oligonucleotides from the solid phase carrier to free the oligonucleotides. Then, the crude oligonucleotides were precipitated with ethanol, and the supernatant was discarded by high-speed centrifugation. The crude oligonucleotides were obtained by repeating two times, and the precipitate was resuspended in DEPC water. The crude oligonucleotides were purified by ion pairing HPLC method, and the collected products were dried to powder in a vacuum centrifugal dryer. The purified products were dissolved in DEPC water and analyzed by TOF LC-MS. The concentration of the oligonucleotides was determined, and the required volumes of equimolar sense and antisense chains were calculated. The equimolar sense and antisense chains were mixed evenly, and double-stranded chains were prepared by annealing method by heating at 95°C for 5 minutes and then cooling naturally to room temperature. The source of isoglycerol nucleotides can be found in the preparation method of Example 2, and other modified nucleosides are prepared by conventional methods or purchased conventionally.
[0104] Table 1: Sense and antisense strand sequences of unmodified siRNA.
[0105]
[0106]
[0107]
[0108]
[0109]
[0110]
[0111] Example 2 Preparation of isoglycerol nucleotides and VPU-S
[0112] 2.1 Preparation of isoglycerol nucleotides
[0113] 2.1.1 Synthesis of compound 1-1
[0114]
[0115] The raw material 5-methylpyrimidine-2,4(1H,3H)-dione (10g, 79.4mmol) was dissolved in anhydrous pyridine and anhydrous toluene, and benzoyl chloride was added. The reaction system was stirred at room temperature overnight, and then the reaction mixture was concentrated to dryness under reduced pressure, 320mL of 1,4-dioxane was added, and K2CO3 aqueous solution (180mL) was added, and the system was stirred at room temperature overnight. The reaction solution was extracted with DCM and the organic liquid was separated. The organic liquid was dried over Na2SO4 and concentrated to dryness under reduced pressure. The concentrate was slurried with DCM, the solid was filtered out, and it was dried to obtain product 1.
[0116] 1 H NMR(500MHz, DMSO-d6), δ11.33(s,1H),7.95(d,J=9.5Hz,2H),7.77(t,J=7.5Hz,1H),7.64–7.58(m,2H),7.52(s,1H),1.82(s,3H).LCMS: Found 231[M+H] + .
[0117]
[0118] Weigh compound (s)-soketal (5.0 g, 38 mmol) and DMAP (370 mg, 3.0 mmol) into a three-necked flask, add DCM and TEA, protect with nitrogen, add TBDPSCl dropwise at room temperature, and stir at room temperature overnight. After TLC and LC-MS monitoring of the reaction are complete, transfer the reaction mixture to a separatory funnel, wash with NaHCO3 solution and water in turn, dry the organic layer with anhydrous Na2SO4, filter and spin dry. Purify by column to obtain compound 2.
[0119]
[0120] Weigh compound 2 (12 g, 32 mmol), add MeOH and DCM to dissolve, carefully drop concentrated hydrochloric acid diluted with MeOH, and stir at room temperature. After TLC and LC-MS monitoring, remove the reaction solvent by vacuum rotary evaporation. Purify by column to obtain compound 3.
[0121] 1 H NMR (500MHz, DMSO-d6), δ7.70-7.62(m,4H),7.50-7.39(m,6H),4.61(d,J=4.5Hz,1H),4.43(t,J=5.6 Hz,1H),3.66-3.54(m,3H),3.49(dt,J=10.2,4.8Hz,1H),3.39(dt,J=10.6,4.9Hz,1H),1.00(s,9H).
[0122]
[0123] The raw material 3 (3.0 g, 9.1 mmol) and DMAP (77 mg, 0.63 mmol) were dissolved in anhydrous pyridine (40 mL), and DMTrCl (3.7 g, 10.9 mmol) was added. The system was stirred at room temperature for 3 h, and then 10 mL of MeOH was added and stirred for 0.5 h. The reaction solution was concentrated to dryness under reduced pressure and separated by column chromatography to obtain product 4.
[0124] 1 H NMR (500MHz, DMSO-d6), δ7.65–7.49(m,4H),7.49–7.34(m,8H),7.31–7.24(m,6H),7.21(dd,J=5.8,3.8Hz,1H),6.88–6.81(m,4H) ,3.81(d,J=5.4Hz,1H),3.72(s,7H),3.63(d,J=5.6Hz,2H),3.13(dd,J=9.1,4.8Hz,1H),3.00(dd,J=9.1,5.7Hz,1H),0.88(s,9H).
[0125]
[0126] Under N2, compound 1 (800 mg, 3.47 mmol), compound 4 (1.98 g, 3.13 mmol), and triphenylphosphine (911 mg, 3.47 mmol) were dissolved in anhydrous THF. The system was cooled to 0-5°C, DIAD was added, and the system was stirred at room temperature overnight. The reaction solution was concentrated to dryness under reduced pressure and separated by column chromatography to obtain product 5.
[0127] 1 H NMR (500MHz, Chloroform-d), δ7.94–7.83 (m, 3H), 7.62 (dt, J = 8.0, 1.5Hz, 6H), 7.53 (s,2H),7.49–7.39(m,11H),7.38–7.32(m,3H),7.29(dd,J=8.5,2.7Hz,4H),7.18(d ,J=2.1Hz,5H),6.85–6.82(m,5H),4.98(h,J=5.4,4.6Hz,2H),3.89(d,J=4.8Hz,1H) ,3.80(s,7H),3.78–3.71(m,1H),3.55–3.44(m,1H),1.97–1.93(m,3H),1.09(s,9H)
[0128]
[0129] Compound 5 (1.4 g, 1.63 mmol) was dissolved in THF (14 mL) and TBAF was added. The system was stirred at room temperature for 0.5 h. The reaction solution was added to 200 mL of water and extracted with DCM. The organic solution was dried over Na2SO4, concentrated under reduced pressure, and separated by column chromatography to obtain a white foamy solid product 6.
[0130] 1 H NMR (500MHz, Chloroform-d), δ7.93–7.87(m,2H),7.62(t,J=7.5Hz,1H),7.43(t,J=7.7Hz,2H),7.37(d,J=7.3Hz,2H),7.34(s,1H),7.32–7.27( m,4H),7.26(s,4H),6.84(d,J=8.4Hz,4H),4.73–4.65(m,1H),4.04–3.8 7(m,2H),3.80(s,6H),3.53(ddd,J=36.4,10.4,5.6Hz,2H),1.92(s,3H).
[0131] LCMS:Found 605[MH] - .
[0132]
[0133] Under N2, compound 6 (0.55 g, 0.91 mmol) and DIPEA (585 mg, 4.54 mmol) were dissolved in THF (, and 2-cyanoethyl N,N-diisopropylchlorophosphoramidite was added. The system was stirred at room temperature for 1 h. The reaction solution was then concentrated under reduced pressure and separated by column chromatography to obtain product 1-1.
[0134] 1 H NMR(500MHz,Chloroform-d),δ7.94–7.86(m,2H),7.62(t,J=7.4Hz,1H),7.48–7.41(m,2H),7.38(d d,J=7.5,3.5Hz,2H),7.34–7.27(m,4H),7.23(d,J=7.1Hz,1H),7.16(d,J=5.7Hz,1H),6.83(dt,J=8 .8,2.0Hz,4H),5.00–4.87(m,1H),3.98–3.82(m,2H),3.79(s,6H),3.77–3.65(m,2H),3.58–3.44(m ,4H),2.54(dt,J=10.0,6.2Hz,2H),1.89(d,J=5.1Hz,3H),1.20–1.13(m,6H),1.09(d,J=6.8Hz,6H).
[0135] LCMS: Found 669[M-137] - ,722[M-84] - .
[0136] 2.1.2 Synthesis of Compound 1-2
[0137]
[0138] Compound 1 (2.08 g, 1.0 eq), 1-1-4 (5.5 g, 1.0 eq), PPh3 (4.6 g, 2.0 eq) were dissolved in dioxane, DEAD was added under air, and the system was ultrasonicated for 30 min. The reaction solution was concentrated under reduced pressure, and the obtained crude product was separated by column chromatography to obtain product 2.
[0139] LMCS:853.37, found 855[M+H] + .
[0140]
[0141] Compound 2 (2.6 g, 1.0 eq) was dissolved in THF (210 mL), and TBAF (12 mL, 4.0 eq, 1 mol / L THF) was added. The system was stirred at room temperature for 1 h. The reaction solution was then concentrated under reduced pressure, added to a saturated aqueous NaHCO3 solution, and extracted with DCM. The organic liquid was washed with a saturated aqueous NaHCO3 solution until no TBAF remained. The organic liquid was separated, dried, and concentrated. The crude product was separated by column chromatography to obtain an off-white foamy solid 3.
[0142] 1H NMR (500MHz, Chloroform-d) δ, 9.12 (s, 1H), 8.68 (s, 1H), 8.13 (s, 1H), 8.07–8.00 (m, 2H), 7.62 (t, J = 7.4Hz, 1H), 7.53 (t, J=7.6Hz,2H),7.23–7.07(m,9H),6.72(dd,J=11.5,8.6Hz,4H),4.72–4.57(m,2H),4.22–4.07(m,2H),3.81–3.65(m,8H).
[0143] LCMS: 616.25, found 616 [M+H] + .
[0144]
[0145] Under N2, compound 3 (1.3 g, 1.0 eq) and DIPEA (1.36 g, 5.0 eq) were dissolved in THF (13 mL), 2-cyanoethyl N,N-diisopropylchlorophosphoramidite was added, and the system was stirred at room temperature for 1 h. The reaction solution was concentrated under reduced pressure, and the obtained crude product was separated by column chromatography to obtain an off-white solid compound 1-2.
[0146] 1 H NMR(500MHz,Chloroform-d)δ,9.06(s,1H),8.75(d,J=4.0Hz,1H),8.09(dt,J=43.0,5.5Hz,3H),7.76–7.49(m,3H ),7.26(s,3H),7.23–7.13(m,6H),6.76(dd,J=8.3,4.2Hz,4H),5.17–4.96(m,1H),4.25(ddt,J=23.2,12.2,6.1Hz, 1H),4.08(ddd,J=38.7,10.9,5.6Hz,1H),3.77(d,J=4.6Hz,6H),3.74–3.70(m,1H),3.65–3.56(m,2H),3.46(dq,J =11.7,6.0Hz,2H),2.61(d,J=17.1Hz,1H),2.50(dq,J=17.4,5.9Hz,2H),1.26(d,J=4.5Hz,5H),1.16–1.07(m,7H).
[0147] LCMS: 815.36, found 733 [M-82] - .
[0148] 2.1.3 Synthesis of compounds 1-3
[0149]
[0150] Compound 1 (2.0 g, 1.0 eq) was mixed with pyridine (100 mL), and isobutyric anhydride (6.0 mL, 2.0 eq) was added. The system was reacted at 115 °C for 2 h. After the reaction solution cooled to room temperature, it was concentrated. 50 mL of MeOH was added to the concentrate, and the mixture was slurried at room temperature for 15 min. The solid was filtered out and dried to obtain an off-white solid product 2.
[0151] 1 H NMR (500MHz, DMSO-d6) δ, 11.45 (s, 1H), 10.69 (s, 1H), 7.79 (d, J = 7.0Hz, 1H), 7.13 (d ,J=7.1Hz,1H),2.71(hept,J=6.8Hz,1H),1.06(d,J=6.9Hz,6H).LCMS:181.09, found 182[M+H] + .
[0152]
[0153] Under N2, compound 2 (2.0 g, 1.0 eq)), 1-1-4 (6.9 g, 1.0 eq)), and PPh3 (3.74 g, 1.3 eq) were dissolved in dioxane, DIAD was added in an ice bath, and the system was stirred at room temperature overnight. The reaction solution was concentrated under reduced pressure, and the crude product was separated by column chromatography to obtain a white foam solid product 3.
[0154] 1 H NMR(500MHz,Chloroform-d)δ8.34(d,J=5.5Hz,1H),7.81–7.71(m,2H),7.65–7.57(m ,4H),7.45–7.36(m,4H),7.31–7.29(m,5H),7.25–7.14(m,5H),6.86–6.81(m,2H),6.8 0–6.72(m,4H),5.43(t,J=5.2Hz,1H),3.99(qd,J=10.6,5.4Hz,2H),3.76(d,J=2.4Hz, 6H),3.53–3.41(m,2H),2.55(dq,J=13.9,6.9Hz,1H),1.27–1.24(m,6H),0.94(s,9H).
[0155] LCMS:795.37, found 754[MH] - .
[0156]
[0157] Compound 3 (3.6 g, 1.0 eq) was dissolved in THF (215 mL) and TBAF was added. The system was stirred at room temperature for 1 h. The reaction mixture was then concentrated under reduced pressure, DCM and saturated NaHCO3 aqueous solution were added, and the organic liquid was separated. The organic liquid was continuously washed with saturated NaHCO3 until no TBAF remained. The organic liquid was dried and concentrated, and the crude product was separated by column chromatography to obtain compound 4.
[0158] 1 H NMR(500MHz,Chloroform-d)δ8.42–8.31(m,1H),8.14(s,1H),7.92–7.80(m,1H),7.47–7.38(m,1H),7.32–7.25(m,6H),7.17(d,J=8.8Hz,3H),6.91–6. 71(m,4H),5.31–5.13(m,1H),4.01–3.87(m,3H),3.79(d,J=11.4Hz,6H),3. 41(ddd,J=30.1,9.8,5.3Hz,1H),2.59–2.54(m,1H),1.25(d,J=7.0Hz,6H).
[0159] LCMS: 557.25, found 556 [MH] - .
[0160]
[0161] Under N2, compound 4 (1.6 g, 1.0 eq) and DIPEA (1.82 g, 5.0 eq) were dissolved in THF, and 2-cyanoethyl N,N-diisopropylchlorophosphoramidite was added. The system was stirred at room temperature for 1 h. The reaction mixture was then concentrated under reduced pressure, and the concentrate was separated by column chromatography to obtain a white foamy solid 1-3.
[0162] 1H NMR(500MHz,Chloroform-d)δ8.36(d,J=5.8Hz,1H),7.95(d,J=5.6Hz,1H),7.78(d,J=5.8Hz,1H),7.40(dd,J=8.1,3.9Hz, 2H),7.29(dt,J=9.1,2.9Hz,4H),7.22(d,J=5.1Hz,3H),7.17(dt,J=8.1,4.2Hz,1H),6.78(dt,J=9.0,4.6Hz,4H),5.49(h,J =5.5Hz,1H),4.08–3.97(m,1H),3.88(dq,J=13.0,6.9Hz,1H),3.76(d,J=6.7Hz,6H),3.71(p,J=6.3Hz,2H),3.52(dq,J=10 .7, 6.8Hz, 2H), 3.40 (dq, J=11.3, 6.2, 5.4Hz, 2H), 2.54 (tq, J=13.1, 6.8Hz, 3H), 1.25 (d, J=6.9Hz, 6H), 1.16–1.07 (m, 12H).
[0163] LCMS:757.36,found 620[M-137] - .
[0164] 2.1.4 Synthesis of Compounds 1-4
[0165]
[0166] Compound 1 (2.0 g, 1.0 eq) was mixed with DMF (10 mL), and acetic anhydride (2.22 mL, 2.6 eq) was added. The system was stirred at 100 °C for 2 h. After the reaction solution was cooled to room temperature, the solid was filtered out, washed with a small amount of ethanol, and vacuum dried to obtain an off-white solid compound 2.
[0167] 1 H NMR (500MHz, DMSO-d6) δ, 12.26 (s, 1H), 11.66 (s, 1H), 8.44 (s, 1H), 2.83 (s, 4H), 1.14 (d, J = 6.8Hz, 6H).
[0168]
[0169] Compound 2 (1.0 g, 1.0 eq), DIPEA (0.98 g, 2.0 eq) and pyridine were mixed, and diphenylaminocarbonyl chloride (1.2 eq) was added, and the system was stirred at room temperature overnight. Ethanol (10 mL) was added to the reaction solution, and after stirring at room temperature for 10 min, the solvent was removed by concentration under reduced pressure, and the crude product was added to ethanol and water. The system was stirred at 100 ° C for 2 h. After the reaction solution was cooled to room temperature, the solid was filtered out and vacuum dried to obtain an off-white solid compound 3.
[0170] 1 H NMR (500MHz, DMSO-d6) δ13.51(s,1H),10.53(s,1H),8.40(s,1H),7.46(dt,J=15. 3,7.7Hz,8H),7.32(t,J=7.3Hz,2H),2.80(p,J=6.9Hz,1H),1.09(d,J=6.8Hz,6H).
[0171] LCMS:415.16, found 417[M+H] + .
[0172]
[0173] Under N2, compound 3 (1.45 g, 1.1 eq), 1-1-4 (2.0 g, 1.0 eq), and PPh3 (1.66 g, 2.0 eq) were dissolved in dioxane, and DIAD was added. The reaction system was stirred at 65°C overnight. The reaction solution was filtered to remove the solid, and the filtrate was concentrated under reduced pressure. The crude product was separated by column chromatography to obtain an off-white foam solid compound 4.
[0174] 1 H NMR(500MHz,Chloroform-d)δ7.95(s,1H),7.76(s,1H),7.72–7.63(m,2H),7.55(td,J=7.3,1.5Hz, 1H),7.51–7.40(m,9H),7.39–7.32(m,6H),7.22(d,J=2.8Hz,2H),7.20–7.14(m,3H),7.10(dd,J=10. 3,8.7Hz,4H),6.76–6.66(m,4H),4.78(q,J=5.6Hz,1H),4.13–4.03(m,2H),3.73(d,J=4.0Hz,6H),3. 71–3.67(m,1H),3.56(dd,J=9.9,4.5Hz,1H),3.07(s,1H),1.19(dd,J=6.8,1.8Hz,6H),0.91(s,9H).
[0175]
[0176] Compound 4 (2.36 g, 1.0 eq) was dissolved in THF, TBAF was added, and the system was stirred at room temperature for 20 min. The reaction mixture was added to a saturated aqueous NaHCO3 solution, and after DCM extraction, the organic solution was washed with a saturated aqueous NaHCO3 solution until no TBAF remained. The organic solution was dried and concentrated, and the crude product was separated by column chromatography to obtain an off-white foam solid compound 5.
[0177] 1 H NMR(500MHz,Chloroform-d)δ8.01(d,J=7.0Hz,2H),7.45(d,J=7.8Hz,4H),7.37(d,J= 7.7Hz,4H),7.26–7.19(m,4H),7.13(dt,J=23.9,8.2Hz,5H),7.05(d,J=8.5Hz,2H),6. 67(dd,J=16.7,8.5Hz,4H),5.78(s,1H),4.38(dd,J=9.0,4.4Hz,1H),4.17–4.10(m,2H ),3.82–3.72(m,2H),3.70(d,J=8.6Hz,6H),2.56(p,J=6.9Hz,1H),1.28–1.23(m,6H).
[0178] LCMS:791.33, found 793[M+H] + .
[0179]
[0180] Compound 5 (1.42 g, 1.0 eq) and DIPEA (1.16 g, 5.0 eq) were dissolved in THF under N2, 2-cyanoethyl N,N-diisopropylchlorophosphoramidite was added, and the system was stirred at room temperature for 1 h. The reaction solution was concentrated under reduced pressure, and the obtained crude product was separated by column chromatography to obtain an off-white foamy solid 1-4.
[0181] 1H NMR(500MHz,Chloroform-d)δ8.06(d,J=8.6Hz,1H),7.87(d,J=7.5Hz,1H),7.44(d,J=7.9Hz,4H),7.35(t,J=7.7Hz,4H),7.27(s,2H ),7.25–7.19(m,4H),7.13(td,J=8.9,6.3Hz,5H),6.73(ddd,J=8.4,5.4,2.4Hz,4H),4.91(t,J=5.9Hz,1H),4.26–4.15(m,1H),4.05– 3.85(m,1H),3.74(d,J=2.6Hz,6H),3.61(s,2H),3.60–3.51(m,2H),3.49–3.38(m,2H),3.07(s,1H),2.51(t,J=6.3Hz,1H),2.45(td, J=6.2,3.4Hz,1H),1.26–1.23(m,6H),1.10(dd,J=6.8,4.6Hz,6H),1.03(d,J=6.8Hz,3H),0.98(d,J=6.8Hz,3H).LCMS:991.44,found 661[M-300] - .
[0182] 2.2 Preparation of VPU-S
[0183] Compound 1: (2R,3R,4R,5R)-5-(3-benzoyl-2,4-dioxo-3,4-dihydropyrimidine-1(2H)-
[0184] 2-((E)-2-(dimethoxyphosphoryl)vinyl)-4-(methylthio)tetrahydrofuran-3-yl(2-cyanoethyl)diisopropylphosphoramidite
[0185] Preparation of (2R,3R,4R,5R)-5-(3-benzoyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-((E)-2-(di methoxyphosphoryl)vinyl)-4-(methylthio)tetrahydrofuran-3-yl(2-cyanoethyl)diisopropylphosphoramidite) (Compound 1)
[0186] 2.2.1
[0188] Preparation of (2R,3R,9aR)-3-hydroxy-2-(hydroxymethyl)-2,3,3a,9a-tetrahydro-6H-furo[2',3':4,5]oxazolo[3,2-a]pyrimidin-6-one (Compound 1-2): Compound 1-1 (30 g, 122.9 mmol), diphenyl carbonate (31.6 g, 147.5 mmol), sodium bicarbonate (825 mg, 9.8 mmol) and DMF (150 mL) were mixed and stirred at 100 ° C for 4 h. After cooling to room temperature, the reaction solution was added dropwise to MTBE (1.5 L), and the reaction mixture was stirred at room temperature for 15 min. The solid was filtered off and the solid was slurried with MeOH (150 mL) at room temperature for 15 min. The solid was filtered off and dried to obtain 23.0 g of an off-white solid product (yield 83.0%). LCMS (ESI): m / z 227 [M+H] + . 2.2.2
[0190] Preparation of 1-((2R,3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-(methylthio)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (Compound 1-3): Compound 1-2 (10 g, 44.2 mmol) was dissolved in DMF (100 mL), sodium thiomethoxide (14.8 g, 212.4 mmol) was added, and the reaction system was stirred at room temperature for 1 h. The reaction solution was adjusted to pH 6-7 with 6N HCl, and the insoluble matter was filtered off. The filtrate was concentrated and separated by column chromatography (DCMDCM / MeOH=20:1) to obtain 12 g (y: 99.0%) of the product as a light yellow solid. LCMS (ESI): m / z 275 [M+H] + . 2.2.3
[0192] Preparation of 1-((2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxy-3-(methylthio)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (Compound 1-4): Compound 1-3 (12 g, 43.8 mmol) was dissolved in anhydrous pyridine (120 mL), DMTrCl (17.8 g, 52.6 mmol) was added, and the system was stirred at room temperature for 1 h. The reaction solution was concentrated, and the concentrate was dissolved in DCM, washed with water, dried over sodium sulfate, concentrated, and separated by column chromatography (PE / DCM / EA=1:1:1DCM / MeOH=20:1) to obtain 13.4 g (yield 53.1%) of the product as a yellow foamy solid. LCMS: 576, found 575[MH] -.1H NMR (500MHz, DMSO-d6) δ11.35(s,1H),7.55(d,J=8.1Hz,1H),7.42(d,J=7.7 Hz,2H),7.28(tt,J=20.0,7.4Hz,7H),6.96–6.87(m,4H),5.97(d,J=5.2Hz,1 H),5.71(d,J=4.2Hz,1H),5.37(d,J=8.1Hz,1H),4.54(td,J=6.3,3.2Hz,1H ),4.19(q,J=4.8Hz,1H),3.74(s,6H),3.40–3.35(m,1H),3.30–3.24(m,2H). 2.2.4
[0194] Preparation of 1-((2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-((tert-butyldimethylsilyl)oxy)-3-(methylthio)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (Compound 1-5): Compound 1-4 (13.4 g, 23.3 mmol) and DBU (7.3 mL, 48.8 mmol) were dissolved in anhydrous DCM (270 mL), TBSCl (7.0 g, 46.5 mmol) was added, and the reaction mixture was stirred at room temperature overnight. The reaction solution was washed with water, dried over sodium sulfate, concentrated, and separated by column chromatography (PE / EA=10:1DCM / MeOH=20:1) to obtain 10.2 g (yield 63.3%) of the product as an off-white foamy solid. LCMS: 690, found 689[MH] -.1H NMR(500MHz,Chloroform-d)δ8.62(d,J=11.6Hz,1H),7.50(d,J=8.2Hz,1H),7.41–7.31(m,2H),7.23(t,J=8.8Hz,3H), 7.19–7.15(m,2H),7.11(dd,J=13.0,5.8Hz,1H),7.04(d,J=8.7Hz,1H),6.77–6.66(m,4H),5.63(t,J=2.9Hz,1H),5.28 (dd,J=8.1,2.2Hz,1H),4.57–4.39(m,1H),4.28–4.19(m,1H),3.67(s,6H),3.44(dd,J=10.7,5.7Hz,1H),3.28(dd,J=1 0.6, 3.1Hz, 1H), 3.00 (ddd, J=78.1, 6.6, 4.5Hz, 1H), 1.92 (d, J=12.7Hz, 3H), 0.77 (d, J=9.6Hz, 9H), 0.06--0.10 (m, 6H). 2.2.5
[0196] Preparation of 1-((2R, 3R, 4R, 5R)-4-((tert-butyldimethylsilyl)oxy)-5-(hydroxymethyl)-3-(methylthio)tetrahydrofuran-2-yl)pyrimidine-2,4(1H, 3H)-dione (Compound 1-6): Compound 1-5 (9.18 g, 13.3 mmol) was dissolved in DCM (92 mL), dichloroacetic acid (4.4 mL, 53.2 mmol) was added, and the reaction mixture was stirred at room temperature for 1 h. Then the reaction solution was adjusted to pH 7-8 with saturated NaHCO3, washed with saturated sodium chloride, dried with sodium sulfate, and concentrated. The concentrate was separated by column chromatography (DCMDCM / MeOH=30:1) to obtain 4.47 g of yellow solid product (yield 86.6%). LCMS: 388, found 389 [M+H] + .1H NMR (500MHz, DMSO-d6) δ11.26(s,1H),7.85(d,J=8.2Hz,1H),5.61(dd,J=8.4,3.3Hz,2H),5.01(t,J=4.4Hz,1H),4 .27–4.16(m,2H),3.59(tdd,J=11.9,10.1,8.1,4.4Hz,2H),2.05(s,3H),0.75(s,9H),-0.00(s,3H),-0.12(s,3H). 2.2.6
[0198] Preparation of dimethyl ((E)-2-((2R, 3R, 4R, 5R)-3-((tert-butyldimethylsilyl)oxy)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-(methylthio)tetrahydrofuran-2-yl)vinyl)phosphonate (Compound 1-7): Compound 1-6 (4.4 g, 11.3 mmol) was dissolved in anhydrous THF (120 mL), DMAP (7.21 g, 17.0 mmol) was added at 0-5°C, and the system was stirred at room temperature for 3 h. The reaction solution was quenched with saturated Na2S2O3, the pH was adjusted to 7-8 with saturated NaHCO3, and extracted with DCM. The extract was dried over sodium sulfate and concentrated to obtain 1-6A. Tetramethylmethylene diphosphate (6.54 g, 22.7 mmol) was dissolved in anhydrous THF (100 mL), potassium tert-butoxide (2.54 g, 22.7 mmol) was added at 0-5°C, and the system was stirred at room temperature for 15 min. 1-6A (dissolved in 20 mL of anhydrous THF) was added, and the reaction solution was stirred at room temperature for 1 h. The reaction solution was added to saturated sodium chloride, extracted with DCM, the DCM layer was separated, dried, and concentrated under reduced pressure. Column chromatography (DCM / Aceton=5:1) was used to obtain 2.6 g of the product (yield 46.7%) as an off-white foamy solid. LCMS (ESI): m / z 493 [M+H] + . 2.2.7
[0200] Preparation of dimethyl ((E)-2-((2R, 3R, 4R, 5R)-5-(3-benzoyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-((tert-butyldimethylsilyl)oxy)-4-(methylthio)tetrahydrofuran-2-yl)vinyl)phosphonate (Compound 1-8): Compound 1-7 (1.6 g, 3.25 mmol), DIPEA (545 mg, 4.23 mmol) were dissolved in anhydrous DCM (32 mL), and BzCl (453 ul, 3.90 mmol) was added. The reaction mixture was stirred at room temperature overnight. The reaction solution was washed with saturated NaCl, dried, concentrated, and separated by column chromatography (PE / DCM / MeOH=50:50:1DCM / MeOH=50:1) to obtain 1.91 g (yield 98.9%) of the product as an off-white foamy solid. LCMS (ESI): m / z 597 [M+H] + . 2.2.8
[0202] Preparation of dimethyl ((E)-2-((2R, 3R, 4R, 5R)-5-(3-benzoyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxy-4-(methylthio)tetrahydrofuran-2-yl)vinyl)phosphonate (Compound 1-9): Compound 1-8 (1.9 g, 3.19 mmol) and TEA (1.2 mL, 4.97 mmol) were dissolved in THF (40 mL), and TEA·3HF (2.67 mL, 15.9 mmol) was added. The reaction mixture was stirred at room temperature overnight. The reaction solution was concentrated under reduced pressure and separated by column chromatography (PE / DCM / MeOH=50:50:1DCM / MeOH=50:1) to obtain 1.2 g (yield 76.1%) of the product as an off-white foamy solid. LCMS: 482, found 483 [M+H] + . 1 H NMR(500MHz,Chloroform-d)δ8.01–7.90(m,2H),7.76(d,J=8.2Hz,1H),7.67(t,J=7 .4Hz,1H),7.52(t,J=7.8Hz,2H),6.83(ddd,J=22.1,17.2,4.7Hz,1H),6.10–5.99(m, 1H),5.87(d,J=8.3Hz,1H),5.72(d,J=2.1Hz,1H),5.14(dd,J=5.2,2.9Hz,1H),4.38 (d,J=2.1Hz,1H),3.93–3.56(m,7H),3.32(dd,J=5.4,2.1Hz,1H),2.16(s,3H).2.2.9
[0203] Preparation of (2R,3R,4R,5R)-5-(3-benzoyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-((E)-2-(dimethoxyphosphoryl)vinyl)-4-(methylthio)tetrahydrofuran-3-yl(2-cyanoethyl)diisopropylphosphoramidite (Compound 1): Compound 1-9 (1.25 g, 2.59 mmol) and DIPEA (1.34 g, 10.4 mmol) were dissolved in anhydrous THF (20 mL), and cyanoethyl N,N-diisopropylchlorophosphoramidite (600 ul, 2.70 mmol) was added, and the system was stirred at room temperature for 1 h. The reaction mixture was concentrated at 30°C and separated by column chromatography (PE / Acetone=3:1, 2% TEA PE / DCM / Acetone=3:1:1, 2% TEA) to obtain 1.60 g (yield 90%) of the product as an off-white foamy solid. LCMS (ESI): m / z 600 [M-83+H] + ,m / z 547[M-135+H]+ . 1 H NMR (500MHz, Chloroform-d) δ7.94 (dd, J=11.0, 7.9Hz, 2H), 7.84 (d, J=8.3Hz, 1H), 7.66 (q, J=7.1Hz, 1H), 7.51 (q, J=7. 4Hz,2H),6.87(dddd,J=21.9,17.1,9.3,4.2Hz,1H),6.15–5.99(m,2H),5.88(t,J=8.8Hz,1H),5.11(dd,J=17.9,4.4Hz ,1H),4.54(dd,J=16.4,9.6Hz,1H),3.94–3.81(m,1H),3.79(d,J=2.0Hz,6H),3.75–3.69(m,1H),3.60(ddt,J=23.5,10 .4,6.7Hz,2H),3.41(dd,J=56.0,5.1Hz,1H),2.55(dt,J=27.8,5.7Hz,2H),2.21(d,J=14.2Hz,3H),1.23–1.11(m,12H).
[0204] Example 3 In vitro screening of siRNA using liposome transfection method
[0205] Cell culture and 96-well plate transfection: In vitro experiments were performed in Hep3B cells using MEM + 10% FBS + 1× penicillin-streptomycin + 1× non-essential amino acid culture medium. When the cell flattening area reached 80%, the cells were digested with trypsin and the cell density was determined using a Scepter automatic cell counter (Millipore, #PHCC00000). At the same time, siRNA, Opti-MEM and INTERFERin (Polyplus transfection) were mixed in a 96-well plate and incubated at room temperature for 10 minutes. Then, complete culture medium containing Hep3B cells was added to each well, and the 96-well plate was incubated in an incubator at 37°C, 5% CO2 for 24 hours.
[0206] Extraction of mouse primary hepatocytes: Mouse hepatocytes were extracted by collagenase digestion through the inferior vena cava perfusion method. After filtering through a tissue cell filter (BIOLOGIX, 15-1070), the mouse primary hepatocytes with good activity were obtained and resuspended in DMEM medium + 10% FBS + 1× penicillin-streptomycin. The cell density was determined using a Scepter automatic cell counter (Millipore). At the same time, siRNA, Opti-MEM and INTERFERin (Polyplus transfection) were mixed in a 96-well plate and incubated at room temperature for 10 minutes. Then, complete culture medium containing Hep3B cells was added to each well, and the 96-well plate was placed in an incubator at 37°C and 5% CO2 for 24 hours.
[0207] 96-well plate RNA extraction and reverse transcription: Dynabeads mRNA DIRECT kit (Ambion) was used to extract mRNA from 96-well plate cells. The culture medium in the 96-well plate was aspirated, washed once with DPBS, and 50-300 μL of cell lysis buffer was added to each well, followed by 20-100 μL of beads, shake on an oscillator, place the 96-well plate on a magnetic separation rack, aspirate the lysate in the well, add 50-300 μL of washing buffer A to each well, place it on a magnetic separation rack after blowing, aspirate the washing buffer A, then blow up the beads with washing buffer B, transfer them to a new 96-well plate, place it on a magnetic separation rack, aspirate the washing buffer B, and then blow up the beads with buffer B and transfer them to a 96-well PCR plate. At the same time, prepare the reversal reagent, place the 96-well PCR plate on a magnetic separation rack, aspirate the washing buffer B, add 20 μL of the reversal reagent to each well, seal the plate with a sealing film, and incubate it at 25°C for 10 minutes on a PCR instrument, then incubate it at 37°C for two hours, then at 85°C for 5 minutes, cool it to 4°C, and the reverse transcription is completed.
[0208] Real-time fluorescence quantitative PCR: After reverse transcription, place the 96-well plate on a magnetic separation rack until the beads are adsorbed to the bottom, aspirate the reverse reagent, add the prepared QPCR system to the 96-well PCR plate, seal the plate with a sealing film, and perform PCR on the StepOnePlus real-time PCR system (applied biosystems).
[0209] Data were analyzed using the ΔΔCt method and normalized using cells transfected with 1 nM of the negative control sequence.
[0210] The sequence of the negative control AD-1955 is: CUUACGCUGAGUACUUCGAdTdT (SEQ ID NO. 205) UCGAAGUACUCAGCGUAAGdTdT (SEQ ID NO. 206).
[0211] The siRNA sequences in Table 1 were modified to obtain Tables 2-4.
[0212] Table 2 describes the sequences of multiple siRNA modified sense strands.
[0213]
[0214]
[0215] Table 3 describes the sequences of various siRNA modified antisense strands.
[0216]
[0217] Table 4 describes the modified siRNA duplex sequences.
[0218]
[0219]
[0220]
[0221] Table 5 shows the screening results of modified siRNA double-strands in Hep3B cells at a concentration of 10 nM.
[0222]
[0223] Table 6 shows the screening results of modified siRNA double-strands in Hep3B cells at a concentration of 1 nM.
[0224]
[0225]
[0226] Table 7 shows the screening results of modified siRNA double-strands at a concentration of 10 nM in mouse primary hepatocytes.
[0227]
[0228]
[0229] Table 8 shows the screening results of modified siRNA double-strands delivered by Galnac at a concentration of 10 nM in rat primary hepatocytes.
[0230]
[0231] Table 9 shows the screening results of modified siRNA double-strands delivered by Galnac at a concentration of 10 nM in mouse primary hepatocytes.
[0232]
[0233] Next, we further optimized the modification of sequences BBD-4005, 4012, 4021, and 4026, and evaluated the above sequences with better activity using the GalNAc delivery method in primary mouse hepatocytes.
[0234] Example 4 Extraction of primary mouse hepatocytes, 96-well plate RNA extraction, inversion and real-time fluorescence quantitative PCR (same method as Example 3)
[0235] Data were analyzed using the ΔΔCt method and assay normalized using cells transfected with 1 nM AD-1955.
[0236] Table 10 describes various modified sense strand sequences.
[0237] Modify the name of the positive chain Modify the sense strand sequence 5'-3' BBD-4005SM1 mC*mU*mAmGmAmGfGmAfGfGfAmUmGmGmAmAmCmUmGmCmA BBD-4005SM2 mC*mU*mAmGmAmGfGmAdGfGfAmUmGmGmAmAmCmUmGmCmA BBD-4005SM3 mC*mU*mAmGmAmGfGmAfGdGfAmUmGmGmAmAmCmUmGmCmA BBD-4005SM4 mC*mU*mAmGmAmGfGmAfGfGdAmUmGmGmAmAmCmUmGmCmA BBD-4005SM5 mC*mU*mAmGmAmGmGmAfGfGdAmUmGmGmAmAmCmUmGmCmA BBD-4005SM6 mC*mU*mAmGmAmGmGmAfGfGfAmUmGmGmAmAmCmUmGmCmA BBD-4005SM7 mC*mU*mAmGmAmGmGmAfGdGfAmUmGmGmAmAmCmUmGmCmA BBD-4005SM8 mC*mU*mAmGmAmGmGmAdGfGfAmUmGmGmAmAmCmUmGmCmA BBD-4012SM1 mG*mC*mAmGmUmGfGmAfCfAfGmUmGmAmGmGmAmCmUmUmA BBD-4012SM2 mG*mC*mAmGmUmGfGmAfCfAdGmUmGmAmGmGmAmCmUmUmA BBD-4012SM3 mG*mC*mAmGmUmGmGmAfCfAdGmUmGmAmGmGmAmCmUmUmA BBD-4012SM4 mG*mC*mAmGmUmGmGmAfCfAfGmUmGmAmGmGmAmCmUmUmA BBD-4012SM5 mG*mC*mAmGmUmGfGmAdCfAfGmUmGmAmGmGmAmCmUmUmA BBD-4012SM6 mG*mC*mAmGmUmGfGmAfCdAfGmUmGmAmGmGmAmCmUmUmA BBD-4012SM7 mG*mC*mAmGmUmGmGmAfCdAfGmUmGmAmGmGmAmCmUmUmA BBD-4012SM8 mG*mC*mAmGmUmGmGmAdCfAfGmUmGmAmGmGmAmCmUmUmA BBD-4012SM9 mA*mG*mUmGmGmAfCmAfGfUdGmAmGmGmAmCmUmUmCmUmA BBD-4021SM9 mA*mG*mUmGmGmAfCmAfGfUdGmAmGmGmAmCmUmUmCmUmA BBD-4026SM2 mC*mU*mUmUmCmCfGmUfGfUdCmUmGmUmGmAmUmCmAmCmA BBD-4101SM1 Invab*mC*mCmAmGmAmGfGmAfGfGdAmUmGmGmAmAmCmUmGmCmA BBD-4101SM2 Invab*mC*mCmAmGmAmGfGmAfGfGdAmUmGmGmAmAmCmUmGmCmAInvab BBD-4101SM3 Invab*mC*mCmAmGmAmGmGmAfGfGdAmUfGmGmAmAmCmUmGmCmAInvab BBD-4101SM4 Invab*mC*mCmAmGmAmGmGmAfGmGfAmUfGmGmAmAmCmUmGmCmAInvab BBD-4102SM1 Invab*mC*mCmAmGmAmGfGmAfGfGdAmUmGmGmAmAmCmUmGmCmA BBD-4102SM2 Invab*mC*mCmAmGmAmGfGmAfGfGdAmUmGmGmAmAmCmUmGmCmAInvab BBD-4102SM3 Invab*mC*mCmAmGmAmGmGmAfGfGdAmUfGmGmAmAmCmUmGmCmAInvab BBD-4102SM4 Invab*mC*mCmAmGmAmGmGmAfGmGfAmUfGmGmAmAmCmUmGmCmAInvab AD-1700871-SM mCmUmAmGmAmGmGmAfGfGfAmUmGmGmAmAmCmUmGmCmA AD-1700555-SM mC*mU*mAmUmGmAmCmAfGfCfAmUmCmAmAmAmUmUmUmCmU
[0238] Table 11 describes various modified antisense strand sequences.
[0239]
[0240]
[0241]
[0242]
[0243] Table 12 describes various modified double-stranded sequences.
[0244]
[0245]
[0246]
[0247]
[0248]
[0249]
[0250]
[0251]
[0252] Table 13 shows the results of the screening experiment of modified siRNA double-strands delivered by Galnac at a concentration of 10 nM in primary hepatocytes of wild-type mice.
[0253]
[0254] Table 14 shows the screening results of modified siRNA double-strands in Hep3B cells at a concentration of 0.3 nM.
[0255]
[0256] Example 5 Evaluation of the effect of BBD-4005 on CIDEB expression in the liver in AAV8-hCIDEB mice (3 mg / kg)
[0257] The effects of the various modified BBD-4005, BBD-4012, BBD-4021 and BBD-4026 sequences on hCIDEB expression in the liver were evaluated in mice expressing hCIDEB.
[0258] 1. Adenovirus Integration of hCIDEB
[0259] 2. By 1.5×10 11 Purified recombinant AAV8 virus particles were injected into 6-8 week old female mice (C57BL / 6) to obtain transgenic mice stably expressing hCIDEB.
[0260] 2. Drug administration
[0261] 14 days after the mice were injected with the virus, the mice were divided into groups, with 4 mice in each group. siRNA was dissolved in physiological saline and injected subcutaneously at a dose of 3 mg / kg.
[0262] 3. Liver sampling and testing
[0263] The liver was harvested at different time points after siRNA injection, and RNA in the liver tissue was extracted by TRI REAGENT (MRC, Catalog No.: TR118), and the extracted RNA was reverse transcribed into cDNA using PrimeScript RT regent Kit (Takara, Catalog No.: RR047A). The prepared QPCR system was added to a 96-well PCR plate, sealed with a plate sealer, and QPCR was performed on the StepOnePlus real-time PCR system (appliedbiosystems) to detect the expression of hCIDEB.
[0264] The liver was harvested 14 and 31 days after siRNA injection to detect hCIDEB expression. The results are shown in Table 15. When the dosage was 3 mg / kg, the different modified sequences had different in vivo activity expressions, and multiple sequences showed significant target gene degradation effects in mice.
[0265] Table 15 evaluates the effect of BBD-4005 on CIDEB expression in the liver in AAV8-hCIDEB mice.
[0266]
[0267] The above data show that the activity of BBD-4005 sequences with different modifications is higher than that of other sequences. Next, we will further screen the optimal siRNA doublet targeting CIDEB from aspects such as sequence base optimization and modification optimization of the sense and antisense chains.
[0268] Example 6 Detection of the activity of the optimized BBD-4005 sequence in primary hepatocytes of AAV8-hCIDEB mice
[0269] We selected two positive sequences from Alnylam (L96-AD-1700555 and L96-AD-1700871, see Table 12 for specific sequences and modifications) as reference controls, performed base optimization on the candidate BBD-4005 sequence, introduced VPU and Invab modifications into the antisense strand, and performed liposome transfection and free uptake experiments in AAV8-hCIDEB mouse primary hepatocytes.
[0270] Table 16 shows the screening experimental results of modified siRNA double-strands at different concentrations in AAV8-hCIDEB mouse primary hepatocytes.
[0271]
[0272] The results showed that after modifying base pairing, VPU modification or Invab modification, the optimized BBD-4005 sequences - BBD-4101.11 and BBD-4102.11 showed better activity than the positive reference.
[0273] Next, we further optimized the modifications of sequences BBD-4101.11 and BBD-4102.11 and evaluated the activity of these sequences in primary mouse hepatocytes using liposome transfection and GalNAc delivery or in vivo.
[0274] Example 7 Detection of the effect of positive strand modification on the activity of BBD-4101 and BBD-4102 sequences in AAV8-hCIDEB mice
[0275] Table 17 shows the screening experimental results of modified siRNA double-strands at different concentrations in AAV8-hCIDEB mouse primary hepatocytes.
[0276]
[0277]
[0278] Based on the pairing of 21 / 23 and 21 / 21, we also optimized the modification of the positive chain, mainly including two combinations: 1. Fluorine modification at positions 7, 9, and 10, methoxy modification at position 10, and DNA modification at position 11 (BBD-4101.21, BBD-4102.21); 2. Fluorine modification at positions 9, 11, and 13 (BBD-4101.41, BBD-4102.41). The results showed that in the pairing of 21 / 23 and 21 / 21, the second positive chain modification had better activity, and this type of modification can be considered in the future. Next, we will use the hCIDEB expression level as an evaluation indicator to explore the in vivo activity of the above modifications in AAV8-hCIDEB mice. The results are shown in Table 18.
[0279] Table 18 shows the effects of different modifications of the antisense and sense chains on sequence activity in AAV8-hCIDEB mice.
[0280]
[0281] The results showed that the overall activity of BBD-4101.41 lasted for a long time, and the fluorinated modifications at positions 9, 11, and 13 of the positive chain may be the optimal modifications of the 4101 sequence. Both the 4101-modified sequence and the 4102-modified sequence were more active than the positive references AD-1700871 and AD-1700555.
[0282] Example 8 Detection of the effect of positive strand modification on the activity of BBD-4101 sequence in AAV8-hCIDEB mice
[0283] Table 19 explores the effects of different modifications of the sense strand on sequence activity in AAV8-hCIDEB mice.
[0284]
[0285] The in vivo activities of the sequences modified with the positive chain in Table 18 were explored based on the 21 / 23 pairing. The results still showed that the fluorinated modifications at positions 9, 11, and 13 (BBD-4101.41) had a longer duration of activity.
[0286] Example 9 Detection of the effect of antisense strand modification on the activity of BBD-4101 sequence in AAV8-hCIDEB mice
[0287] Next, based on the version with two invabs on the sense chain, we combined the different modifications of the sense chain and the antisense chain to explore the effects of these modifications on the activity of the 4101 and 4102 sequences. They can be divided into three groups: 1. DNA modification at position 12, fluorine modification at positions 14 and 15 on the antisense chain (BBD-4101.31, BBD-4101.41, BBD-4101.21); 2. Fluorine modification at position 7, DNA modification at position 12, fluorine modification at positions 14 and 15 on the antisense chain (BBD-4101.33, BBD-4101.43, BBD-4101.23); 3. Fluorine modification at position 8, DNA modification at position 12, fluorine modification at positions 14 and 15 on the antisense chain (BBD-4101.34, BBD-4101.44, BBD-4101.24). The effects of these modifications on the activity of the BBD-4101 sequence were explored by liposomal transfection and free uptake in AAV8-hCIDEB mouse primary hepatocytes.
[0288] Table 20 shows the screening experimental results of modified siRNA double-strands at different concentrations in AAV8-hCIDEB mouse primary hepatocytes.
[0289]
[0290] The results showed that the three different groups of antisense modifications and the combinations of the positive chain modifications in Table 18 had little effect on the activity of the BBD-4101 sequence.
[0291] Example 10 Exploring the Effects of Different VP Modifications of the Antisense Strand on Sequence Activity in AAV8-hCIDEB Mice
[0292] We performed different VP modifications based on the 21 / 21 paired sequence BBD-4102, including VPU, VPU-S, VPU-12, and VPU-8, and explored the effects of these modifications on the activity of BBD-4102 in vitro and in vivo in AAV8-hCIDEB mice.
[0293] Table 21 shows the screening experimental results of modified siRNA double-strands at different concentrations in AAV8-hCIDEB mouse primary hepatocytes.
[0294]
[0295]
[0296] In vitro results showed that for BBD-4101 and BBD-4102 sequences, VPU and VPU-S modifications showed higher activity overall, regardless of free uptake or liposome transfection experiments. Next, we explored the effects of different VP modifications of the antisense strand on the in vivo activity of the 21 / 21 paired BBD-4101 sequence, and the results are shown in Table 22.
[0297] Table 22 shows the effects of different VP modifications of the antisense chain on sequence activity in AAV8-hCIDEB mice.
[0298]
[0299] In vivo results showed that the sequences modified with VPU and VPU-S (BBD-4102.41, BBD-4102.44) had higher in vivo activity. Example 11 Evaluation of the in vitro metabolic stability of BBD-4102 with different VP modifications in the liver
[0300] 1. Use DEPC water to accurately dilute the compound sequence to a working solution with a concentration of 10 μM.
[0301] 2. Preparation of liver homogenate: Weigh 200 mg of mouse liver, add 1 mL of potassium phosphate buffer solution and 5 magnetic beads, and homogenize three times in a grinder at 60 Hz, 30 s / time to obtain 200 mg / mL liver homogenate.
[0302] 3. Preparation of 72h samples: Take 17μL of 10μM test compound / positive compound working solution, add 153μL liver homogenate to mix, vortex for 30s, take 75μL of the compound and liver homogenate mixed solution into an EP tube, the number of parallel samples is 2, place it in a 37℃ incubator for 72h, and take out 50μL after incubation.
[0303] Preparation of 4.0h samples: Take 75μL of liver homogenate in an EP tube, with 2 parallel samples, and incubate in a 37°C incubator for 72h. After incubation, take out 45μL of liver homogenate, add 5μL of 10μM test compound / positive compound, and mix well.
[0304] 5. After incubation, add 5 μL of 50 μg / mL internal standard to each tube of sample, mix well, add 100 μL of lysis buffer to each tube, vortex for 30 seconds, and let stand for 20 minutes.
[0305] 6. After all samples were treated with appropriate pretreatment methods, the supernatant was taken for instrumental analysis. Then the relative residual rate (%) was calculated as follows: (72h compound content / 0h compound content) × 100%.
[0306] The results are shown in Table 23.
[0307] Table 23 evaluates the in vitro metabolic stability of BBD-4102 with different VP modifications in the liver.
[0308] VP modification siRNA duplex Remaining proportion of antisense strand after 72h (%) Remaining proportion of positive chain after 72h (%) VPU BBD-4102.41 89.20 44.58 VPU-S BBD-4102.44 106.17 24.45 VPU-12 BBD-4102.45 94.38 8.33 VPU-8 BBD-4102.46 97.03 1.71
[0309] The results showed that after 72 hours of liver homogenate incubation, the remaining proportions of the test sequences were relatively high, among which the BBD-4102 sequence modified with the antisense chain VPU-S had the highest stability.
[0310] Experimental Example 12: Exploring the effect of antisense strand modification with UNA or isoGNA-T on sequence activity
[0311] It has been reported that UNA modification or isoGNA-T modification can improve the stability of the sequence and reduce its toxicity in vivo. Therefore, we further introduced UNA and isoGNA-T modifications at the 7th position of the antisense chain based on the 21 / 21 and 21 / 23 pairing versions, combined with the above-screened VPU and VPU-S modifications, to explore the activity of BBD-4102 and BBD-4101 in vitro and in vivo in mice.
[0312] Table 24 shows the screening experimental results of modified siRNA double-strands at different concentrations in AAV8-hCIDEB mouse primary hepatocytes.
[0313]
[0314] The results showed that UNA and isoGNA-T modifications had no significant effect on improving sequence activity. Except for BBD-4102.42, which had a low activity, the activities of the remaining sequences were high and the differences were not significant. Next, we will select the 21 / 21 pairing version and explore the activity of sequences containing these modification combinations through in vivo experiments.
[0315] Table 25 explores the effects of different antisense chain modifications on sequence activity in wild-type mice.
[0316]
[0317] The test results on the seventh day after drug addition showed that based on the sequence base optimization, the addition of UNA and isoGNA-T had little effect on the activity of BBD-4102. Overall, BBD-4102.41 can be used as an ideal sequence for subsequent targeting of CIDEB.
[0318] Example 13 Evaluation of the pre-treatment effects of BBD-4101 and BBD-4102 in a high-fat diet-induced NASH mouse model
[0319] 1. Administration
[0320] 20 C57 female mice, weighing 20-25g, were randomly divided into 5 groups, 4 mice in each group, and set up control group, model group, and drug administration group. The control group was fed with normal feed every day, and the model group and drug administration group were fed with NASH feed (A06071302, CDAHFD, Choline-deficient, l-amino acid-defined, high-fat diet) every day. The siRNA dosage of the drug administration group was 3mg / kg, the administration volume was 5mL / kg, the solvent was normal saline, and the administration method was subcutaneous injection. The control group and the model group were given the same dose of solvent in the same administration method.
[0321] 2. Liver sampling and testing
[0322] 29 days after siRNA injection, the animals were killed and the livers were removed. RNA was extracted from the liver tissues using TRI REAGENT (MRC, Catalog No.: TR118), and the extracted RNA was reverse transcribed into cDNA using PrimeScript RT regent Kit (Takara, Catalog No.: RR047A). The prepared QPCR system was added to a 96-well PCR plate, sealed with a plate sealer, and PCR was performed on a StepOnePlus real-time fluorescence quantitative PCR system (applied biosystems). The expression of the CIDEB gene and the expression of genes related to liver disease were detected (results are shown in Figure 1 In addition, the remaining liver tissues were stained with HE, and the liver fibrosis of each group was observed (see the results). Figure 2 ).
[0323] Real-time fluorescence quantitative PCR results showed that BBD-4101.41 and BBD-4102.41 restored the expression of fibrosis marker genes (mTNFA, mMCP-1) in the high-fat diet-induced NASH model in mice. HE results showed that BD-4101.41 and BBD-4102.41 could significantly improve the level of liver fibrosis induced by a high-fat diet. It can be seen that BBD-4101 and BBD-4102 have a good pre-treatment effect in the high-fat diet-induced NASH model.
[0324] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. A siRNA for inhibiting the expression of DFFA-like effector B (Cell death-inducing DFFA-like effector b, CIDEB) in cells, comprising a sense strand and an antisense strand, wherein the sense strand and the antisense strand are complementary, and the siRNA is selected from at least one pair or a modified sequence thereof: a) BBD-4101, the sense strand of which is shown in SEQ ID NO.201, and the antisense strand of which is shown in SEQ ID NO.202; b) BBD-4102, the sense strand of which is shown in SEQ ID NO.203, and the antisense strand of which is shown in SEQ ID NO.
204.
2. The siRNA according to claim 1, wherein The sense strand comprises no more than 3, 2, 1 or 0 unmodified nucleotides, the modified nucleotides in the sense strand comprise 2'-O-methyl modified nucleotides, 2'-deoxynucleotides, 2'-fluorine modified nucleotides, terminal inverted abasic residues, locked nucleic acids, respectively, and the sense strand contains 1, or 2, or 3 phosphorothioate bonds at the 5'-end; And the antisense strand includes no more than 3, 2, 1 or 0 unmodified nucleotides, the modified nucleotides in the antisense strand include 2'-O-methyl modified nucleotides, 2'-deoxynucleotides, 2'-fluorine modified nucleotides, terminal 5'-(E)-vinylphosphonate nucleotides and analogs thereof, open-ring nucleic acid nucleotides or isoglycerol nucleotides, respectively, and the antisense strand contains 1-3 phosphorothioate bonds at the 5'-end and 3'-end.
3. The siRNA according to claim 2, wherein The 5'-(E)-vinylphosphonate nucleotides and analogs thereof are uridine-5'-(E)-vinylphosphonate and analogs thereof, which are selected from one of the following structures: ; or ; Where: R is XG, X is selected from: -C(R 8 )(R 9 )-, -S-; R 8 and R 9 are independently selected from: H, C1-C6 alkyl, halogen; G is selected from: H, halogen, cyano, C1-C 10 Alkyl, C2-C 10 Alkenyl, C2-C 10 Alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkylmethyl, C1-C 10 Alkoxy, halogen-substituted C1-C 10 Alkyl, hydroxy substituted C1-C 10 Alkyl, C1-C6 alkoxy substituted C1-C 10 Alkyl, amino substituted C1-C 10 Alkyl, C1-C6 alkylamino substituted C1-C 10 Alkyl, cyano substituted C1-C 10 alkyl.
4. The siRNA according to claim 3, wherein R is selected from the group consisting of methylthio, ethylthio, ethyl, propyl, allyl, methoxymethyl, methoxyethyl, cyanomethyl and fluoromethyl.
5. The siRNA according to claim 3, wherein The uridine-5'-(E)-vinylphosphonate and its analogs are 2'-S-methyluridine-5'-(E)-vinylphosphonic acid-3'-phosphate or 2'-O-methyluridine-5'-(E)-vinylphosphonic acid-3'-phosphate.
6. The siRNA according to claim 2, wherein The isoglycerol nucleotide modification is shown in formula (I): ; Wherein, M is O or S; Base is selected from any one of purine, adenine, guanine, isoguanine, hypoxanthine, xanthine, C2-modified purine, N8-modified purine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, N6-alkyladenine, O6-alkylguanine, 7-deazapurine, cytosine, 5-methylcytosine, isocytosine, pseudocytosine, uracil, pseudouracil, 2-thiouridine, 4-thiouridine, C5-modified pyrimidine, thymine, indole, 5-nitroindole and 3-nitropyrrole.
7. The siRNA according to claim 6, wherein The modified nucleotide of formula (I) is at least one of the following: 。 8. The siRNA according to any one of claims 1 to 7, wherein When the sense strand of siRNA is 21 nucleotides and the antisense strand is 23 nucleotides, The 3' to 5' modification of the sense strand is as follows: u mA mmmmmmmymdvfmymmmmmmu, The 5'-3' base modifications of the antisense strand are as follows: vpU fmmmmxymmmdmfmfmymmmm m; Or when the sense strand of siRNA is 21 nucleotides and the antisense strand is 21 nucleotides, The 3' to 5' modification of the sense strand is as follows: u mA mmmmmmmymdvfmymmmmmmmu, The 5'-3' base modifications of the antisense strand are as follows: vpU fmmmmxymmmdmfmfmymmm ; Among them, vpU is uridine-5'-terminal-(E)-vinylphosphonate and its analogs, mA is 2'-O-methyladenosine-3'-phospho ester, m is any 2'-O-methyl modified nucleotide, f is any 2'-fluorine modified nucleotide, x is any 2'-O-methyl modified nucleotide or open nucleic acid nucleotide or isoglycerol nucleotide (isoGNA), y is any 2'-O-methyl modified nucleotide or any 2'-fluorine modified nucleotide, d is any 2'-deoxy nucleotide or 2'-fluorine modified nucleotide, v is any 2'-fluorine modified nucleotide or any 2'-O-methyl modified nucleotide or any 2'-deoxy nucleotide, and u is 0-1 inverted abasic residue.
9. The siRNA according to claim 8, wherein The siRNA is a modified duplex of the naked sequence of BBD-4101 or BBD-4102 in Table 12.
10. The siRNA according to claim 9, wherein The siRNA is BBD-4101.11, BBD-4102.11, BBD-4101.21, BBD-4101.24, BBD-4101.31, BBD-4101.41, BBD-4101.33, BBD-4101.43, BBD-4101.34, BBD-4101.44, BBD-4101.45, BBD-4101.46, BBD-4101.48, BBD-4101.49, BBD-4101.410, BBD-4102.21, BBD-4102.24, BBD-4102.25, BBD-4102.26, BBD-4102.41, BBD-4102.42, BBD-4102.43, BBD-4102.44, BBD-4102.45, BBD-4102.46, BBD-4102.47, BBD-4102.
48.
11. The siRNA according to claim 10, wherein The siRNAs are BBD-4102.41, BBD-4102.44, BBD-4102.42, BBD-4102.47, BBD-4102.43, BBD-4102.48, BBD-4101.41, BBD-4101.48, BBD-4101.45, BBD-4101.49, BBD-4101.46, and BBD-4101.410 in Table 12.
12. Use of the siRNA according to any one of claims 1 to 11 in the preparation of a biological preparation or a pharmaceutical preparation for inhibiting the expression of CIDEB.
13. A biological agent or pharmaceutical agent for inhibiting the expression of CIDEB, wherein: The invention comprises the siRNA according to any one of claims 1 to 11, and a targeted delivery ligand or a delivery carrier connected to or encapsulated with the siRNA.
14. The biological preparation or pharmaceutical preparation according to claim 13, wherein: The ligand is an N-acetylgalactosamine derivative; or any liposome or other delivery vehicle that can be specifically delivered to liver cells.
15. The biological preparation or pharmaceutical preparation according to claim 14, wherein: The structure of the N-acetylgalactosamine derivative is as follows: ; or ; or ; or 。 16. The biological or pharmaceutical preparation according to claims 13-15, wherein: The N-acetylgalactosamine derivative is connected to the 3' end of the sense strand of the siRNA as follows: ; or ; or ; or 。 17. Use of the biological preparation or pharmaceutical preparation according to any one of claims 13 to 16 in the preparation of a product for preventing or treating a disease associated with CIDEB.
18. The use according to claim 17, wherein: The diseases associated with CIDEB are hepatitis, liver fibrosis, non-alcoholic fatty liver disease, cirrhosis, alcoholic fatty liver disease, HCV-related cirrhosis, drug-induced liver damage and hepatocellular necrosis; or the diseases associated with CIDEB are diabetes, insulin resistance, hyperglycemia, and various infections caused by diabetes, obesity, metabolic syndrome, and dyslipidemia.
19. The use according to claim 18, wherein: The hepatitis is non-alcoholic steatohepatitis.
Citation Information
Patent Citations
Methods and systems for detecting tissue conditions
CN109790643A
Treatment of liver disease with cell death-inducing DFA-like effect B (CIDEB) inhibitors
CN116685691A
